Literature DB >> 24846412

Indirect CD4+ T-cell-mediated elimination of MHC II(NEG) tumor cells is spatially restricted and fails to prevent escape of antigen-negative cells.

Anders A Tveita1, Fredrik H Schjesvold, Olav Sundnes, Ole Audun W Haabeth, Guttorm Haraldsen, Bjarne Bogen.   

Abstract

Tumor-specific Th1 cells can activate tumor-infiltrating macrophages that eliminate MHC class II negative (MHC II(NEG)) tumor cells. Activated M1-like macrophages lack antigen (Ag) receptors, and are presumably unable to discriminate and thus kill both Ag-positive (Ag(POS)) and Ag-negative (Ag(NEG)) tumor cells (bystander killing). The lack of specificity of macrophage-mediated cytotoxicity might be of clinical importance as it could provide a means of avoiding tumor escape. Here, we have tested this idea using mixed populations of Ag(POS) and Ag(NEG) tumor cells in a TCR-transgenic model in which CD4(+) T cells recognize a secreted tumor-specific antigen. Surprisingly, while Ag(POS) tumor cells were recognized and rejected, Ag(NEG) cells grew unimpeded and formed tumors. We further demonstrated that macrophage-mediated cytotoxicity was spatially restricted to areas dominated by Ag(POS) tumor cells, sparing Ag(NEG) tumor cells in the vicinity. As a consequence, macrophage tumoricidal activity did not confer bystander killing in vivo. The present results offer novel insight into the mechanisms of indirect Th1-mediated elimination of MHC II(NEG) tumor cells.
© 2014 WILEY-VCH Verlag GmbH & Co. KGaA, Weinheim.

Entities:  

Keywords:  Bystander killing; CD4+ T-cell immunotherapy; Macrophage cytotoxicity; Macrophage polarization; Myeloma

Mesh:

Substances:

Year:  2014        PMID: 24846412     DOI: 10.1002/eji.201444659

Source DB:  PubMed          Journal:  Eur J Immunol        ISSN: 0014-2980            Impact factor:   5.532


  9 in total

1.  IAP antagonists induce anti-tumor immunity in multiple myeloma.

Authors:  Marta Chesi; Noweeda N Mirza; Victoria M Garbitt; Meaghen E Sharik; Amylou C Dueck; Yan W Asmann; Ilseyar Akhmetzyanova; Heidi E Kosiorek; Arianna Calcinotto; Daniel L Riggs; Niamh Keane; Gregory J Ahmann; Kevin M Morrison; Rafael Fonseca; Martha Q Lacy; David Dingli; Shaji K Kumar; Sikander Ailawadhi; Angela Dispenzieri; Francis Buadi; Morie A Gertz; Craig B Reeder; Yi Lin; Asher A Chanan-Khan; A Keith Stewart; David Fooksman; P Leif Bergsagel
Journal:  Nat Med       Date:  2016-11-14       Impact factor: 53.440

2.  Limitations of bystander killing in Th1/M1 immune responses against a secreted tumor antigen.

Authors:  Anders Aune Tveita; Ole Audun Haabeth; Bjarne Bogen
Journal:  Oncoimmunology       Date:  2014-12-13       Impact factor: 8.110

3.  Autologous cellular vaccine overcomes cancer immunoediting in a mouse model of myeloma.

Authors:  Marta Mazzocco; Matteo Martini; Antonio Rosato; Elisabetta Stefani; Andrea Matucci; Silvia Dalla Santa; Francesco De Sanctis; Stefano Ugel; Sara Sandri; Giovanna Ferrarini; Tiziana Cestari; Sergio Ferrari; Paola Zanovello; Vincenzo Bronte; Silvia Sartoris
Journal:  Immunology       Date:  2015-06-15       Impact factor: 7.397

4.  Polarity of CD4+ T cells towards the antigen presenting cell is regulated by the Lck adapter TSAd.

Authors:  Greger Abrahamsen; Vibeke Sundvold-Gjerstad; Meseret Habtamu; Bjarne Bogen; Anne Spurkland
Journal:  Sci Rep       Date:  2018-09-06       Impact factor: 4.379

5.  Cognate Interaction With CD4+ T Cells Instructs Tumor-Associated Macrophages to Acquire M1-Like Phenotype.

Authors:  David Eisel; Krishna Das; Elke Dickes; Rainer König; Wolfram Osen; Stefan B Eichmüller
Journal:  Front Immunol       Date:  2019-02-22       Impact factor: 7.561

Review 6.  Dynamic CD8+ T Cell Cooperation with Macrophages and Monocytes for Successful Cancer Immunotherapy.

Authors:  Anaïs Vermare; Marion V Guérin; Elisa Peranzoni; Nadège Bercovici
Journal:  Cancers (Basel)       Date:  2022-07-21       Impact factor: 6.575

7.  CD4+ T-cell killing of multiple myeloma cells is mediated by resident bone marrow macrophages.

Authors:  Ole Audun W Haabeth; Kjartan Hennig; Marte Fauskanger; Geir Åge Løset; Bjarne Bogen; Anders Tveita
Journal:  Blood Adv       Date:  2020-06-23

8.  Tumor-specific CD4+ T cells eradicate myeloma cells genetically deficient in MHC class II display.

Authors:  Anders Tveita; Marte Fauskanger; Bjarne Bogen; Ole Audun Werner Haabeth
Journal:  Oncotarget       Date:  2016-10-11

9.  Tumor Killing by CD4+ T Cells Is Mediated via Induction of Inducible Nitric Oxide Synthase-Dependent Macrophage Cytotoxicity.

Authors:  Marte Fauskanger; Ole Audun Werner Haabeth; Frode Miltzow Skjeldal; Bjarne Bogen; Anders Aune Tveita
Journal:  Front Immunol       Date:  2018-07-23       Impact factor: 7.561

  9 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.